GMP services
Your EU-GMP release point for Europe.
Turnkey GMP processing with a single quality management system in Prague, and your product is market-ready across Europe.
If you grow or manufacture cannabis outside the European Union, the constraint is rarely demand. It is release. Product cannot reach a European pharmacy until a Qualified Person inside the Union has certified the batch against EU-GMP.
Motagon is that release point. We hold both parts of the framework, so we can take your material as an active substance or as a finished medicinal product, and we hold the storage, narcotics and distribution licences that come after it. You keep your brand, your pricing and your customer relationships. We run the regulated infrastructure behind them.
Turnkey EU-GMP services
Most partners use the whole chain. You do not have to.
- 01
EU-GMP processing from Q2 2027
Drying, trimming and repacking of GACP-compliant bulk flower into finished product, at our dedicated EU-GMP processing space in the Czech Republic.
- GACP-compliant bulk flower in
- Drying and trimming under EU-GMP
- Repacking into finished pack sizes
- 02
GMP release, Part I and Part II
Qualified Person certification of finished medicinal products under EU-GMP Part I, and Quality Assurance release of cannabis as an active substance under Part II.
- Batch record review
- QP certification and batch release (Part I)
- QA release of the active substance (Part II)
- Supplier and site qualification, release documentation
- 03
EU-GMP testing
Full quality control of flowers and extracts against the specification agreed in your Technical Quality Agreement, at our qualified laboratory partners under our oversight.
- Flower and extract testing: identity and cannabinoid content
- Microbiological quality and mycotoxins
- Heavy metals, pesticides, residual solvents
- 04
Storage
Licensed storage under GDP conditions, including narcotics storage under Czech licence, with quarantine and released stock held separately.
- Temperature and humidity controlled
- Narcotics-licensed secure area
- Batch-level stock visibility
- 05
Labelling and secondary packing
Labelling and secondary packaging of released product in the language and format the destination market requires, in your artwork or in ours.
- Destination-market labels
- Secondary packaging of released batches
- 06
Distribution
Onward shipment from Prague to Germany, the United Kingdom and other European markets where medical cannabis is legal, through GDP-certified wholesalers.
- Export and narcotics permits
- GDP-compliant, temperature-controlled transport (15 to 25 °C)
- Wholesale routes into each destination market
Two release tracks, and which markets need which
The same flower can be an active substance in one country and a finished medicinal product in the next. The destination market decides the track.
-
Part II
EU-GMP Part II, active substance (API) release
Batch record review, testing and QA release of cannabis as an active pharmaceutical ingredient. Held since 2022.
For the Czech Republic and other markets where medical cannabis is classified as an API and the finished preparation is made in the pharmacy, and for producers supplying API into EU manufacturing.
-
Part I
EU-GMP Part I, finished product (FP) release
Batch record review, quality control, labelling, secondary packaging and Qualified Person certification of finished medicinal products. Held since June 2026.
For Germany and other EU markets where medical cannabis is classified as a finished medicinal product and must be certified as one before it is placed on the market.
Both authorisations are published on the European Medicines Agency’s EudraGMDP database. See our licences.
Where we can ship
A batch released in Prague can move into any European market that permits medical cannabis, subject to that market’s import and narcotics permits and its product registration rules.
- Germany, the largest prescription market in Europe
- United Kingdom, outside the EU, on a separate import route
- Czechia and Poland, where we also sell our own and partner brands
- Other European markets as they open, assessed case by case
Forms we can handle
- Dried flower, labelled and secondary-packed in the pack sizes you supply
- Dried flower, repacked into finished pack sizes at our GMP processing partner from Q2 2027
- Full-spectrum extracts, bottled formats and bulk
- Active substance (API) under Part II
- Pastilles and oral solid forms
- Cartridges and inhalation devices, subject to destination-market registration
- Other finished forms, assessed against our licensed scope
Your brand stays yours
Motagon sells its own Mota® brand and distributes third-party brands. If you are handing us your product, you are entitled to know how that is kept apart.
-
Commercial separation
Your pricing, volumes, customer list and launch plans are not visible to the team that sells Mota®. Access is restricted at system level, not by convention.
-
Physical segregation
Your stock is held under your ownership, identified to your batch, and quarantined separately from released goods. It is never pooled with ours.
-
Written into the agreement
Confidentiality, non-solicitation and data handling are set out in the contract before any material moves, alongside the Technical Quality Agreement.
How an engagement starts
- Scoping call. What you produce, where it is grown, which markets you are aiming at, and which of the GMP services you actually need.
- Documentation exchange. Your GMP or GACP status, specifications, stability data and analytical methods, against our licensed scope.
- Technical Quality Agreement. Specification, testing schedule, shelf life and responsibilities, signed by both quality units.
- First shipment and release. Import permit, goods-in, quarantine, testing, certification, release.
We will tell you early if we are not the right partner. That is cheaper for both of us than finding out in month six.